|
To all (the diabetes sufferers and their loved ones)who replied to my questions: Clearly, if you are in favor, for the variety of reasons expressed, then the product will have a measure of acceptance, and a measure of success. But as this specific product will NOT replace the test strip method, nor the accuracy of the latter for the purpose of administering medication, then I still fail to see a valid reason for going long the stock here, sentimentality aside. To compare the accuracy of the Watch to some of the meters of five years ago is unfair. There are strips and meters out now that do not need calibration, that have imbedded chips and software to aid in monitoring and control, and are light-years ahead of similar products made a number of years ago. Yes, constant fingersticks are painful and debilitating , but until a reliable 'non-stick' meter comes along, then the test strip method is not yet obsolete, and this new product not yet the 'real McCoy'. Unfortunately. This is all I am saying. A long position here is pure spec on the future fortunes of CYGN, and not,imo, because of a major break-through. Perhaps, a future watch will become totally reliable, (as will affordable artificial pancreas, and an insulin pill). I hope so. But that time is not yet here by the very statements made by the FDA Advisory. |
